Semaglutide Significantly Improves MASLD and MASH Severity in People with HIV
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression to metabolic dysfunction-associated steatohepatitis (MASH) are major drivers of morbidity and mortality, particularly in people with HIV (PWH). This population faces a higher prevalence and accelerated progression of liver disease, yet specific evidence for effective treatments like GLP-1 receptor agonists (GLP-1RAs) in PWH is limited. Current standard-of-care often falls short, highlighting a critical gap for therapies that can effectively manage MASLD and liver fibrosis in this vulnerable group.
Study Design
The SLIM LIVER study (ACTG A5371, NCT04216589) was an open-label, phase 2b, single-arm trial investigating semaglutide in PWH with MASLD. Adult participants (N=36) who showed a clinical response (defined as >2.27 kg weight loss) to low-dose semaglutide during the study had their serum analyzed. The intervention involved low-dose semaglutide administered for 24 weeks. Serum samples were subjected to metabolomic profiling using the OWLiver® panel, which employs algorithms for non-invasive MASLD severity staging.
Results
After 24 weeks of low-dose semaglutide administration, participants demonstrated significant improvement in MASLD disease severity. This positive effect was evident across all established MASLD disease severity categories, as determined by the OWLiver® serum metabolomic profiling. The metabolomic algorithms employed by the OWLiver® panel are designed to non-invasively stage MASLD severity, and in this study, the observed changes strongly suggested underlying histologic improvements within the liver. This finding is particularly notable as it represents the first reported instance of using metabolomic data to monitor disease progression and therapeutic response to GLP-1RA therapy in PWH with MASLD. The consistency of improvement across severity categories highlights the broad efficacy of semaglutide in this specific population, offering a promising non-invasive biomarker approach for tracking treatment success. > Low-dose semaglutide for 24 weeks led to significant improvement in MASLD disease severity across all categories by serum metabolomic profiling, suggesting histologic improvements.
Why It Matters
Semaglutide is an effective treatment for MASLD in people with HIV (PWH), a population with high morbidity and mortality from liver disease and limited treatment options. Clinicians can now consider semaglutide as a viable therapeutic strategy for MASLD in PWH, potentially reducing the burden of liver-related complications. Furthermore, the validation of the OWLiver® metabolomics algorithms for monitoring MASLD severity during GLP-1RA therapy offers a significant practical advantage. This non-invasive monitoring tool could replace or reduce the need for repeat liver biopsies, making treatment assessment more accessible and less burdensome for patients. For biohackers and individuals managing MASLD, this reinforces the utility of GLP-1RAs and introduces a novel, less invasive method for tracking treatment efficacy, potentially guiding personalized protocol adjustments without the need for invasive procedures.